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Infections post transplant
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Summary:
Allogeneic bone marrow transplant recipients have sev-
ere impairment of cell-mediated immunity and hence a
higher incidence of mycobacterial infections might be
expected in regions where tuberculosis is common. We
reviewed the case records of 217 patients who
underwent allogeneic bone marrow transplantation
during the period 1986–1999 at our center in India.
Mycobacterial infections were diagnosed in three
patients (1.38%). All patients presented with extrapul-
monary disease. Two patients had disseminated
tuberculosis with one of these being diagnosed on auto-
psy studies. The third patient had tuberculosis involving
the cervical lymph node and dorsal spine. Two patients
treated with antituberculous therapy are well. Infection
with Mycobacterium tuberculosis is not a common prob-
lem in allogeneic bone marrow recipients even in an
endemic area, but when it occurs, it is usually dissemi-
nated with predominantly extrapulmonary involvement.
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Tuberculosis is a major health problem in India with an
annual incidence of 250–500 per 100 000 population and a
prevalence of 2% of the total population over 10 years of
age.1 Patients who undergo allogeneic bone marrow trans-
plantation (BMT) have severely impaired cell-mediated
immunity as a result of their underlying disease, condition-
ing chemotherapy and radiation, graft-versus-host disease
(GVHD) and its treatment.2 A high incidence of tubercu-
losis could be expected in such patients especially in areas
where tuberculosis is common. Large series from Europe
and North America reviewing infections in BMT patients
have reported incidences varying ,0.1 to 2.2%,3,4 while
reports from areas with a high prevalence of tuberculosis
have reported incidences varying from 1.5% to 5%.5,6 We
reviewed the case records of all patients who underwent
allogeneic BMT at our center from 1986 to 1999 to study
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the incidence of tuberculosis in allogeneic bone marrow
recipients in India.
Materials and methods
All patients who underwent allogeneic bone marrow trans-
plantation at our center between 1986 and 1999 were
included in the analysis. Their case records were reviewed
to study the incidence of tuberculosis. The follow-up period
ranged from 2 to 120 months post BMT. All patients were
nursed in HEPA filtered rooms with positive pressure venti-
lation during conditioning chemotherapy and in the
immediate post-transplant period until the absolute neutro-
phil count (ANC) was .500/mm3. Antimicrobial prophy-
laxis given during the period of BMT consisted of flucona-
zole and acyclovir. Cotrimoxazole was added after the
ANC was .1000/mm3 in all recipients. GVHD prophylaxis
consisted of cyclosporine and short course methotrexate.7
A diagnosis of tuberculosis was made on the basis of:
(1) Positive AFB culture for mycobacterium tuberculosis;
(2) biopsy showing caseous necrosis with granulomas
suggestive of tuberculosis.
Results
Of the 217 patients who underwent allogeneic BMT during
the period 1986–1999, three developed tuberculosis.
Their clinical characteristics are shown in Table 1.
UPN 41
A 7-year-old male with ALL in CR2 presented 445 days
after allogeneic BMT with pain and swelling in the neck
and fever of 3 weeks duration. MRI scan of the spine
showed contiguous destruction of C7-D3 spine with
anterior wedging and a resultant spinal gibbus deformity
at D1. A cervical lymph node biopsy was consistent with
tuberculosis. Lymph node samples were positive for AFB
bacilli and cultures confirmed the presence of Mycobacter-
ium tuberculosis. The patient was given antituberculous
therapy (ATT) for 18 months with complete resolution of
his symptoms. He is presently 6 years post BMT and in
complete remission with no evidence of ALL or tuber-
culosis.
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Table 1 Clinical characteristics
UPN No. 41 123 164
Age/Sex 7/M 3/M 40/M
Diagnosis ALL Thalassaemia MDS with fibrosis
major
Conditioning regimen Bu/Cy Bu/Cy Bu/Cy
Acute GVHD and grade Oral mucosa grade II Skin and GI tract grade III Nil
Chronic GVHD Nil Nil Nil
Diagnosis of TB, day post BMT 445 81 13
Therapy at onset of TB Nil CSA CSA
Site of tuberculosis Cervical spine, lymph node Liver, bone marrow Lung, liver, bone marrow,
spleen
Diagnosis Biopsy and culture positive Biopsy positive from liver and Biopsy, post mortem
from lymph node bone marrow
Resolutions of symptoms Yes Yes Expired
TB 5 tuberculosis; ATT 5 anti-tuberculous treatment.
UPN 123
A 3-year-old male with thalassemia major presented 81
days after allogeneic BMT with fever of 2 weeks duration.
He had been treated for a primary complex at the age of 1
year with ATT for 6 months. He was receiving cyclospor-
ine for grade III acute GVHD at the time of the fever. He
was evaluated and diagnosed to have disseminated tubercu-
losis on the basis of granulomas in the liver and bone mar-
row biopsies. He has received 1 year of antituberculous
therapy and is well 40 months post BMT.
UPN 164
A 40-year-old male was diagnosed to have myelodysplastic
syndrome with fibrosis of the bone marrow, on evaluation
for pancytopenia and fever. He was extensively investi-
gated for the cause of the pyrexia, but no etiology could
be established. He had received steroids (prednisolone
1 mg/kg) for 4 weeks as therapy for his pancytopenia with
a cellular marrow. He had an allogeneic BMT and died on
day 13 post BMT with progressive pulmonary infiltrates
and jaundice. Autopsy showed multiple necrotizing granu-
lomata with caseous necrosis and Langhan’s giant cells in
the liver, lung, spleen, hilar lymph nodes and bone marrow,
suggestive of tuberculosis along with disseminated asper-
gillus and candida. AFB cultures were not undertaken, but
AFB stains on the autopsy specimens were positive for acid
fast bacilli.
All patients had extrapulmonary or disseminated tuber-
culosis. Both the patients with an antemortem diagnosis
of tuberculosis responded well to appropriate therapy
with antituberculous drugs with complete resolution of
symptoms.
Discussion
There are few reports on the incidence of tuberculosis in
BMT recipients. The majority of the studies have reported
incidences varying from 0.1 to 2.2%, while only a single
study from Hong Kong has reported a much higher inci-
dence of tuberculosis close to 5%.2–4,8,9 It is generally
believed that an immunosuppressed state will magnify the
infectious diseases that are endemic in a locality and since
Asian countries have a higher incidence of tuberculosis, one
would expect the incidence of tuberculosis to be higher in
such populations.
Chronic GVHD, immunosuppressive therapy and total
body irradiation (TBI) have been shown to be risk factors
associated with the development of tuberculosis.10,11
Patients with chronic GVHD have a marked delay of T
cell subset recovery with low numbers of CD41 cells being
present.12 This period of impairment of T cell function may
be indefinite in the presence of chronic GVHD. Immuno-
suppression results in failure to acquire adoptive immunity,
while TBI hampers normal function of alveolar macro-
phages. Both contribute to an increased predisposition to
tuberculosis.13 The number of patients with tuberculosis is
too small in our series to allow any correlation.
The incidence of tuberculosis in our patients of 1.38%
is similar to the incidence described in other series, but is
lower than figures reported from Hong Kong.5 One patient
(UPN 123) was treated for primary complex at the age of
1 year and had reactivation of tuberculosis, while the other
two patients had primary progressive tuberculosis. All the
patients had normal chest radiographs prior to BMT. Inter-
estingly, all patients who developed tuberculosis had pre-
dominantly extrapulmonary forms of tuberculosis with two
patients having disseminated disease and one developing
spinal and lymph node involvement. This pattern of infec-
tion is analogous to the forms of tuberculosis seen in
patients with HIV infection and in renal transplant recipi-
ents, where an increased incidence of extrapulmonary
forms of tuberculosis has been reported.14–16 The early reac-
tivation and presentation of tuberculosis in one patient in
this series may have been because of the steroids he had
received prior to BMT. The other two patients responded
very well to long-term antituberculous therapy in spite of
extrapulmonary manifestations. One patient (UPN 41) had
culture proven Mycobacterium tuberculosis, while patient
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third patient (UPN 123) had necrotizing granulomata in the
liver and bone marrow. Although cultures are not available
in the other two patients, in a country endemic for tubercu-
losis presence of acid fast bacilli on a smear is considered
to represent Mycobacterium tuberculosis only and not to
be due to atypical mycobacteria such as Mycobacterium
avium intracellulare (MAIC) or Mycobacterium kansasii
(WHO Guidelines for Clinicians in South East Asia).17 In
the patient with disseminated granulomata, there was a
good response to four standard anti-tuberculous drugs with
complete resolution of symptoms. This is the first report
of disseminated tuberculosis occurring in allogeneic bone
marrow transplant recipients.
The incidence of tuberculosis in allogeneic bone marrow
transplant recipients in this series from India is low.
Prophylactic INH does not seem to be warranted in patients
undergoing allogeneic BMT in India. Since most patients
present with extrapulmonary forms of tuberculosis, a high
degree of suspicion and early identification is required to
allow antituberculous therapy to be started as soon as
possible.
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